Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 49

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 49
---
 RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the controlling persons. RA Capital serves as investment advisor for the Fund, the Account, and the Nexus Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Exchange Act, of any of our securities held by the Fund, the Account, or the Nexus Fund. The Fund and the Nexus Fund have delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s and the Nexus Fund’s portfolio, including the shares of our Common Stock reported herein. Because the Fund and the Nexus Fund have divested themselves of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days’ notice, the Fund and the Nexus Fund disclaim beneficial ownership of the securities they hold for purposes of Section 13(d) of the Exchange Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Exchange Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Exchange Act, of any of our securities beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities listed above other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act. The principal business address for each of the entities listed above is 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. |

| (2) | Based on information contained in the Schedule 13G/A filed with the SEC on January 21, 2025 by entities affiliated with Canaan XI L.P. (“Canaan XI”) and in a Form 4 subsequently filed by Nina Kjellson, a former director of the Company, on February 7, 2025. Consists of (i) 3,700,705 shares of our Common Stock held by Canaan XI and (ii) 443,885 shares of our Common Stock held by Canaan 2020+ Co-Investment L.P.—Series 7 (“Canaan Series 7”). Canaan Partners XI LLC (“Canaan XI GP”) is the general partner of Canaan XI and may be deemed to beneficially own 3,700,705 shares of Common Stock. Canaan Partners 2020